Clinical Trial Update: Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism [Phase 3]

View source ↗

Summary

Phase 3 trial comparing apixaban to dalteparin for reducing blood clots in cancer-associated venous thromboembolism has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Vein Thrombosis
• Deep Vein Thrombosis
• Venous Thromboembolism

Drugs mentioned

• Apixaban (apixaban)
• Dalteparin (dalteparin)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Cerebral Vein Thrombosis, Deep Vein Thrombosis | Phase 3 | Status: COMPLETED | Results posted: 2019-12-24